{"pmid":32325475,"title":"The post-lockdown period should be used to acquire effective therapies for future resurgence in SARS-Cov-2 infections.","text":["The post-lockdown period should be used to acquire effective therapies for future resurgence in SARS-Cov-2 infections.","COVID-19 will be with us through the remainder of 2020 and almost certainly beyond. New Zealand needs a viable strategy to protect its populace until a vaccine is developed and in wide use. Until that time, it makes sense to protect the population by putting in place treatments that will be safe and effective, such as the use of convalescent sera and the use of direct-acting anti-virals. These treatments should be sourced externally or made locally, but steps in this direction must now begin as the lockdown ends. New Zealand has the scientists, the facilities and the will to make this happen, but the support of the government and the population will be needed if this plan is to succeed.","N Z Med J","Krause, Kurt L","Furneaux, Richard","Benjes, Paul","Brimble, Margaret","Davidson, Tony","Denny, William","Harris, Lawrence","Hinkley, Simon","Tyler, Peter","Ussher, James E","Ward, Vernon","32325475"],"abstract":["COVID-19 will be with us through the remainder of 2020 and almost certainly beyond. New Zealand needs a viable strategy to protect its populace until a vaccine is developed and in wide use. Until that time, it makes sense to protect the population by putting in place treatments that will be safe and effective, such as the use of convalescent sera and the use of direct-acting anti-virals. These treatments should be sourced externally or made locally, but steps in this direction must now begin as the lockdown ends. New Zealand has the scientists, the facilities and the will to make this happen, but the support of the government and the population will be needed if this plan is to succeed."],"journal":"N Z Med J","authors":["Krause, Kurt L","Furneaux, Richard","Benjes, Paul","Brimble, Margaret","Davidson, Tony","Denny, William","Harris, Lawrence","Hinkley, Simon","Tyler, Peter","Ussher, James E","Ward, Vernon"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32325475","week":"202017|Apr 20 - Apr 26","source":"PubMed","topics":["Treatment"],"weight":1,"locations":["New Zealand","New Zealand"],"countries":["New Zealand"],"countries_codes":["NZL|New Zealand"],"_version_":1664895932774219776,"score":8.518259,"similar":[{"pmid":32306555,"title":"Forced Disruption of Anatomy Education in Australia and New Zealand: An Acute Response to the Covid-19 Pandemic.","text":["Forced Disruption of Anatomy Education in Australia and New Zealand: An Acute Response to the Covid-19 Pandemic.","Australian and New Zealand universities commenced a new academic year in February/March 2020 largely with 'business as usual'. The subsequent COVID-19 pandemic imposed unexpected disruptions to anatomical educational practice. Rapid change occurred due to government-imposed physical distancing regulations from March 2020 that increasingly restricted anatomy laboratory teaching practices. Anatomy educators in both these countries were mobilized to adjust their teaching approaches. This study on anatomy education disruption at pandemic onset within Australia and New Zealand adopts a social constructivist lens. The research question was \"What are the perceived disruptions and changes made to anatomy education in Australia and New Zealand during the initial period of the Covid-19 pandemic, as reflected on by anatomy educators?\". Thematic analysis to elucidate ''the what and why'' of anatomy education was applied to these reflections. Eighteen anatomy academics from ten institutions participated in this exercise. The analysis revealed loss of integrated 'hands-on' experiences, and impacts on workload, traditional roles, students, pedagogy and anatomists' personal educational philosophies. The key opportunities recognized for anatomy education included: enabling synchronous teaching across remote sites, expanding offerings into the remote learning space, and embracing new pedagogies. In managing anatomy education's transition in response to the pandemic, six critical elements were identified: community care, clear communications, clarified expectations, constructive alignment, community of practice, ability to compromise and adapt and continuity planning. There is no doubt that anatomy education has stepped into a yet unknown future in the island countries of Australia and New Zealand.","Anat Sci Educ","Pather, Nalini","Blyth, Phil","Chapman, Jamie A","Dayal, Manisha R","Flack, Natasha A M S","Fogg, Quentin A","Green, Rodney A","Hulme, Anneliese K","Johnson, Ian P","Meyer, Amanda J","Morley, John W","Shortland, Peter J","Strkalj, Goran","Strkalj, Mirjana","Valter, Krisztina","Webb, Alexandra L","Woodley, Stephanie J","Lazarus, Michelle D","32306555"],"abstract":["Australian and New Zealand universities commenced a new academic year in February/March 2020 largely with 'business as usual'. The subsequent COVID-19 pandemic imposed unexpected disruptions to anatomical educational practice. Rapid change occurred due to government-imposed physical distancing regulations from March 2020 that increasingly restricted anatomy laboratory teaching practices. Anatomy educators in both these countries were mobilized to adjust their teaching approaches. This study on anatomy education disruption at pandemic onset within Australia and New Zealand adopts a social constructivist lens. The research question was \"What are the perceived disruptions and changes made to anatomy education in Australia and New Zealand during the initial period of the Covid-19 pandemic, as reflected on by anatomy educators?\". Thematic analysis to elucidate ''the what and why'' of anatomy education was applied to these reflections. Eighteen anatomy academics from ten institutions participated in this exercise. The analysis revealed loss of integrated 'hands-on' experiences, and impacts on workload, traditional roles, students, pedagogy and anatomists' personal educational philosophies. The key opportunities recognized for anatomy education included: enabling synchronous teaching across remote sites, expanding offerings into the remote learning space, and embracing new pedagogies. In managing anatomy education's transition in response to the pandemic, six critical elements were identified: community care, clear communications, clarified expectations, constructive alignment, community of practice, ability to compromise and adapt and continuity planning. There is no doubt that anatomy education has stepped into a yet unknown future in the island countries of Australia and New Zealand."],"journal":"Anat Sci Educ","authors":["Pather, Nalini","Blyth, Phil","Chapman, Jamie A","Dayal, Manisha R","Flack, Natasha A M S","Fogg, Quentin A","Green, Rodney A","Hulme, Anneliese K","Johnson, Ian P","Meyer, Amanda J","Morley, John W","Shortland, Peter J","Strkalj, Goran","Strkalj, Mirjana","Valter, Krisztina","Webb, Alexandra L","Woodley, Stephanie J","Lazarus, Michelle D"],"date":"2020-04-20T11:00:00Z","year":2020,"_id":"32306555","week":"202017|Apr 20 - Apr 26","doi":"10.1002/ase.1968","keywords":["australia","covid-19 pandemic","new zealand","active learning","gross anatomy education","medical education","online delivery","online practical anatomy","reflective practices","remote learning","student wellbeing","workload"],"source":"PubMed","topics":["Prevention"],"weight":1,"locations":["Australian","New Zealand","Australia","New Zealand","Australia","New Zealand","Australia","New Zealand","Australia","New Zealand"],"countries":["Australia","New Zealand"],"countries_codes":["AUS|Australia","NZL|New Zealand"],"_version_":1664641855781863424,"score":117.8508},{"pmid":32317432,"title":"COVID-19 pandemic: Lessons learned and future directions.","text":["COVID-19 pandemic: Lessons learned and future directions.","Emerging pandemics show that humans are not infallible and communities need to be prepared. Coronavirus outbreak was first reported towards the end of 2019 and has now been declared a pandemic by the World Health Organization. Worldwide countries are responding differently to the virus outbreak. A delay in detection and response has been recorded in China, as well as in other major countries, which led to an overburdening of the local health systems. On the other hand, some other nations have put in place effective strategies to contain the infection and have recorded a very low number of cases since the beginning of the pandemics. Restrictive measures like social distancing, lockdown, case detection, isolation, contact tracing, and quarantine of exposed had revealed the most efficient actions to control the disease spreading. This review will help the readers to understand the difference in response by different countries and their outcomes. Based on the experience of these countries, India responded to the pandemic accordingly. Only time will tell how well India has faced the outbreak. We also suggest the future directions that the global community should take to manage and mitigate the emergency.","Indian J Ophthalmol","Khanna, Rohit C","Cicinelli, Maria Vittoria","Gilbert, Suzanne S","Honavar, Santosh G","Murthy, Gudlavalleti S V","32317432"],"abstract":["Emerging pandemics show that humans are not infallible and communities need to be prepared. Coronavirus outbreak was first reported towards the end of 2019 and has now been declared a pandemic by the World Health Organization. Worldwide countries are responding differently to the virus outbreak. A delay in detection and response has been recorded in China, as well as in other major countries, which led to an overburdening of the local health systems. On the other hand, some other nations have put in place effective strategies to contain the infection and have recorded a very low number of cases since the beginning of the pandemics. Restrictive measures like social distancing, lockdown, case detection, isolation, contact tracing, and quarantine of exposed had revealed the most efficient actions to control the disease spreading. This review will help the readers to understand the difference in response by different countries and their outcomes. Based on the experience of these countries, India responded to the pandemic accordingly. Only time will tell how well India has faced the outbreak. We also suggest the future directions that the global community should take to manage and mitigate the emergency."],"journal":"Indian J Ophthalmol","authors":["Khanna, Rohit C","Cicinelli, Maria Vittoria","Gilbert, Suzanne S","Honavar, Santosh G","Murthy, Gudlavalleti S V"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32317432","week":"202017|Apr 20 - Apr 26","doi":"10.4103/ijo.IJO_843_20","keywords":["covid-19","onehealth","sars-cov-2","pandemic"],"source":"PubMed","topics":["Prevention"],"weight":1,"locations":["China","India","India"],"countries":["China","India"],"countries_codes":["CHN|China","IND|India"],"_version_":1664815087805792257,"score":108.490265},{"pmid":32325471,"title":"Variation in volumes and characteristics of trauma patients admitted to a level one trauma centre during national level 4 lockdown for COVID-19 in New Zealand.","text":["Variation in volumes and characteristics of trauma patients admitted to a level one trauma centre during national level 4 lockdown for COVID-19 in New Zealand.","AIM: The aims of this study were to describe the variation in volumes and types of injuries admitted to a level one trauma centre in New Zealand over two 14-day periods before and during the national level 4 lockdown for COVID-19; and highlight communities at risk of preventable injury that may impact negatively on hospital resources. METHOD: A retrospective, descriptive study of prospectively collected data in the Midland Trauma Registry in New Zealand. RESULTS: Overall there was a reduction of 43% in all injury-related admissions with significant reductions seen in major injury (50% reduction), males (50% reduction) and children aged 0-14 years (48% reduction). Results for ethnicity and persons aged over 14 years were within 3% deviation of this overall 43% reduction. Injuries at home, particularly falls, predominate. CONCLUSION: Despite the significant reduction in admissions during level 4 lockdown, hospitals should continue to provide full services until resource limitations are unavoidable. Immediate messaging is recommended to reduce rates of injury on the farm and at home, specifically falls prevention. Ongoing attention of road users to road safety is essential to reduce the incidence of preventable major injury. These immediate measures can potentially reduce unnecessary pressure on hospital beds and resources during the pandemic.","N Z Med J","Christey, Grant","Amey, Janet","Campbell, Alaina","Smith, Alastair","32325471"],"abstract":["AIM: The aims of this study were to describe the variation in volumes and types of injuries admitted to a level one trauma centre in New Zealand over two 14-day periods before and during the national level 4 lockdown for COVID-19; and highlight communities at risk of preventable injury that may impact negatively on hospital resources. METHOD: A retrospective, descriptive study of prospectively collected data in the Midland Trauma Registry in New Zealand. RESULTS: Overall there was a reduction of 43% in all injury-related admissions with significant reductions seen in major injury (50% reduction), males (50% reduction) and children aged 0-14 years (48% reduction). Results for ethnicity and persons aged over 14 years were within 3% deviation of this overall 43% reduction. Injuries at home, particularly falls, predominate. CONCLUSION: Despite the significant reduction in admissions during level 4 lockdown, hospitals should continue to provide full services until resource limitations are unavoidable. Immediate messaging is recommended to reduce rates of injury on the farm and at home, specifically falls prevention. Ongoing attention of road users to road safety is essential to reduce the incidence of preventable major injury. These immediate measures can potentially reduce unnecessary pressure on hospital beds and resources during the pandemic."],"journal":"N Z Med J","authors":["Christey, Grant","Amey, Janet","Campbell, Alaina","Smith, Alastair"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32325471","week":"202017|Apr 20 - Apr 26","source":"PubMed","topics":["Prevention"],"weight":1,"locations":["New Zealand","New Zealand","New Zealand"],"countries":["New Zealand"],"countries_codes":["NZL|New Zealand"],"_version_":1664895932851814400,"score":104.82737},{"pmid":32117569,"pmcid":"PMC7029759","title":"Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China.","text":["Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China.","A novel coronavirus (2019-nCoV) originating in Wuhan, China presents a potential respiratory viral pandemic to the world population. Current efforts are focused on containment and quarantine of infected individuals. Ultimately, the outbreak could be controlled with a protective vaccine to prevent 2019-nCoV infection. While vaccine research should be pursued intensely, there exists today no therapy to treat 2019-nCoV upon infection, despite an urgent need to find options to help these patients and preclude potential death. Herein, I review the potential options to treat 2019-nCoV in patients, with an emphasis on the necessity for speed and timeliness in developing new and effective therapies in this outbreak. I consider the options of drug repurposing, developing neutralizing monoclonal antibody therapy, and an oligonucleotide strategy targeting the viral RNA genome, emphasizing the promise and pitfalls of these approaches. Finally, I advocate for the fastest strategy to develop a treatment now, which could be resistant to any mutations the virus may have in the future. The proposal is a biologic that blocks 2019-nCoV entry using a soluble version of the viral receptor, angiotensin-converting enzyme 2 (ACE2), fused to an immunoglobulin Fc domain, providing a neutralizing antibody with maximal breath to avoid any viral escape, while also helping to recruit the immune system to build lasting immunity. The sequence of the ACE2-Fc protein is provided to investigators, allowing its possible use in recombinant protein expression systems to start producing drug today to treat patients under compassionate use, while formal clinical trials are later undertaken. Such a treatment could help infected patients before a protective vaccine is developed and widely available in the coming months to year(s).","F1000Res","Kruse, Robert L","32117569"],"abstract":["A novel coronavirus (2019-nCoV) originating in Wuhan, China presents a potential respiratory viral pandemic to the world population. Current efforts are focused on containment and quarantine of infected individuals. Ultimately, the outbreak could be controlled with a protective vaccine to prevent 2019-nCoV infection. While vaccine research should be pursued intensely, there exists today no therapy to treat 2019-nCoV upon infection, despite an urgent need to find options to help these patients and preclude potential death. Herein, I review the potential options to treat 2019-nCoV in patients, with an emphasis on the necessity for speed and timeliness in developing new and effective therapies in this outbreak. I consider the options of drug repurposing, developing neutralizing monoclonal antibody therapy, and an oligonucleotide strategy targeting the viral RNA genome, emphasizing the promise and pitfalls of these approaches. Finally, I advocate for the fastest strategy to develop a treatment now, which could be resistant to any mutations the virus may have in the future. The proposal is a biologic that blocks 2019-nCoV entry using a soluble version of the viral receptor, angiotensin-converting enzyme 2 (ACE2), fused to an immunoglobulin Fc domain, providing a neutralizing antibody with maximal breath to avoid any viral escape, while also helping to recruit the immune system to build lasting immunity. The sequence of the ACE2-Fc protein is provided to investigators, allowing its possible use in recombinant protein expression systems to start producing drug today to treat patients under compassionate use, while formal clinical trials are later undertaken. Such a treatment could help infected patients before a protective vaccine is developed and widely available in the coming months to year(s)."],"journal":"F1000Res","authors":["Kruse, Robert L"],"date":"2020-03-03T11:00:00Z","year":2020,"_id":"32117569","week":"202010|Mar 02 - Mar 08","doi":"10.12688/f1000research.22211.2","keywords":["2019-ncov","ace2","wuhan","coronavirus","neutralizing antibody","outbreak"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["Wuhan","China","Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Oligonucleotides"],"_version_":1664640875055022081,"score":92.371635},{"pmid":32207377,"title":"Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2.","text":["Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2.","Pseudoviruses are useful virological tools because of their safety and versatility, especially for emerging and re-emerging viruses. Due to its high pathogenicity and infectivity and the lack of effective vaccines and therapeutics, live SARS-CoV-2 has to be handled under biosafety level 3 conditions, which has hindered the development of vaccines and therapeutics. Based on a VSV pseudovirus production system, a pseudovirus-based neutralization assay has been developed for evaluating neutralizing antibodies against SARS-CoV-2 in biosafety level 2 facilities. The key parameters for this assay were optimized, including cell types, cell numbers, virus inoculum. When tested against the SARS-CoV-2 pseudovirus, SARS-CoV-2 convalescent patient sera showed high neutralizing potency, which underscore its potential as therapeutics. The limit of detection for this assay was determined as 22.1 and 43.2 for human and mouse serum samples respectively using a panel of 120 negative samples. The cutoff values were set as 30 and 50 for human and mouse serum samples, respectively. This assay showed relatively low coefficient of variations with 15.9% and 16.2% for the intra- and inter-assay analyses respectively. Taken together, we established a robust pseudovirus-based neutralization assay for SARS-CoV-2 and are glad to share pseudoviruses and related protocols with the developers of vaccines or therapeutics to fight against this lethal virus.","Emerg Microbes Infect","Nie, Jianhui","Li, Qianqian","Wu, Jiajing","Zhao, Chenyan","Hao, Huan","Liu, Huan","Zhang, Li","Nie, Lingling","Qin, Haiyang","Wang, Meng","Lu, Qiong","Li, Xiaoyu","Sun, Qiyu","Liu, Junkai","Fan, Changfa","Huang, Weijin","Xu, Miao","Wang, Youchun","32207377"],"abstract":["Pseudoviruses are useful virological tools because of their safety and versatility, especially for emerging and re-emerging viruses. Due to its high pathogenicity and infectivity and the lack of effective vaccines and therapeutics, live SARS-CoV-2 has to be handled under biosafety level 3 conditions, which has hindered the development of vaccines and therapeutics. Based on a VSV pseudovirus production system, a pseudovirus-based neutralization assay has been developed for evaluating neutralizing antibodies against SARS-CoV-2 in biosafety level 2 facilities. The key parameters for this assay were optimized, including cell types, cell numbers, virus inoculum. When tested against the SARS-CoV-2 pseudovirus, SARS-CoV-2 convalescent patient sera showed high neutralizing potency, which underscore its potential as therapeutics. The limit of detection for this assay was determined as 22.1 and 43.2 for human and mouse serum samples respectively using a panel of 120 negative samples. The cutoff values were set as 30 and 50 for human and mouse serum samples, respectively. This assay showed relatively low coefficient of variations with 15.9% and 16.2% for the intra- and inter-assay analyses respectively. Taken together, we established a robust pseudovirus-based neutralization assay for SARS-CoV-2 and are glad to share pseudoviruses and related protocols with the developers of vaccines or therapeutics to fight against this lethal virus."],"journal":"Emerg Microbes Infect","authors":["Nie, Jianhui","Li, Qianqian","Wu, Jiajing","Zhao, Chenyan","Hao, Huan","Liu, Huan","Zhang, Li","Nie, Lingling","Qin, Haiyang","Wang, Meng","Lu, Qiong","Li, Xiaoyu","Sun, Qiyu","Liu, Junkai","Fan, Changfa","Huang, Weijin","Xu, Miao","Wang, Youchun"],"date":"2020-03-25T11:00:00Z","year":2020,"_id":"32207377","week":"202013|Mar 23 - Mar 29","doi":"10.1080/22221751.2020.1743767","keywords":["COVID-19","SARS-CoV-2","neutralization assay","neutralizing antibody","pseudovirus"],"source":"PubMed","locations":["pseudovirus"],"topics":["Treatment"],"weight":1,"_version_":1663352133738561536,"score":90.24382}]}